How does ZYNE compare to other cannabis stocks?

Zynerba Pharmaceuticals (ZYNE) has a market cap of $33.8M and trades at $1.30 per share. You can compare it against 5 sector peers and companies across the cannabis industry.

What are the closest competitors to ZYNE?

The closest competitors to Zynerba Pharmaceuticals by market capitalization include C21 Investments (CXXIF), Vext Science (VEXTF), Cannabis ETF (THCX). These companies operate in similar market cap ranges within the cannabis industry.

Is ZYNE bigger than its peers?

Zynerba Pharmaceuticals has a market capitalization of $33.8M. It ranks among Biotech cannabis companies by market cap, with 2 peers smaller by market cap.

Which cannabis stocks have better margins than ZYNE?

Zynerba Pharmaceuticals has a gross margin of 0.0%. Among its sector peers, 1 companies have higher gross margins.

Where can I compare ZYNE with a specific cannabis stock?

You can use the comparison links on this page to compare Zynerba Pharmaceuticals head-to-head with any cannabis stock listed on Cannabismarketcap. Each comparison shows price, valuation, financial metrics, and growth side by side.

Compare Zynerba Pharmaceuticals (ZYNE) With Other Cannabis Stocks

Head-to-head stock comparisons across price, valuation, financials, and growth metrics

Company

Zynerba Pharmaceuticals (ZYNE)

Price

$1.30

Change

+3.17%

Market Cap

$33.8M

Sector

Biotech

Biotech Sector Peers

All Biotech cannabis companies sorted by market capitalization. Click any ticker to see a detailed head-to-head comparison.

Ticker	Name	Price	Change %	MCap	Revenue	P/S	Gross Margin
JAZZ	Jazz Pharmaceuticals	$178.55	-1.66%	$10.99B	$4.16B	2.6x	0.0%
INNPF	InnocanPharma	$5.07	0.00%	$354.9M	$0	N/A	0.0%
CNVCF	BioHarvest Sciences	$5.71	+1.33%	$57.1M	$0	N/A	0.0%
XXII	22nd Century Group	$3.88	+1.97%	$2.0M	$18.1M	0.1x	36.3%
OVATF	Ovation Science	$0.02	0.00%	$623.3K	$0	N/A	0.0%

Top Matchups by Market Cap

Companies closest to Zynerba Pharmaceuticals in market capitalization — the most meaningful head-to-head comparisons.

CXXIFMSO

C21 Investments

MCap: $33.5M

$0.28+3.61%

Compare

VEXTFMSO

Vext Science

MCap: $34.2M

$0.190.00%

Compare

THCXETF

Cannabis ETF

MCap: $33.2M

$16.60-0.26%

Compare

YOLOETF

AdvisorShares Pure Cannabis ETF

MCap: $33.1M

$2.83-4.88%

Compare

MRMDMSO

MariMed Inc

MCap: $32.3M

$0.08+8.14%

Compare

Cross-Sector Comparisons

Top cannabis companies outside the Biotech sector. Compare across different business models and market segments.

SMGAncillary

Scotts Miracle-Gro

MCap: $3.54B

$60.96+0.96%

Compare

CURLFMSO

Curaleaf Holdings

MCap: $1.80B

$2.36+2.83%

Compare

TPBAncillary

Turning Point Brands

MCap: $1.73B

$90.62+0.69%

Compare

GTBIFMSO

Green Thumb Industries

MCap: $1.54B

$6.56+7.01%

Compare

IIPRREIT

Innovative Industrial Properties

MCap: $1.48B

$52.66-2.34%

Compare

Comparing ZYNE in the Cannabis Market

Zynerba Pharmaceuticals (ZYNE) is a Biotech-sector cannabis company trading at $1.30 per share with a market capitalization of $33.8M. Among its Biotech peers, ZYNE ranks #4 by market cap, with trailing twelve-month revenue of $0 and a gross margin of 0.0%. The stock has moved +3.17% in the current session, trading on the NASDAQ exchange.

When comparing ZYNE against other cannabis stocks, investors should consider key financial metrics including price-to-sales ratio (N/A), revenue growth (0.00% YoY), and balance sheet strength (cash of $0 vs. debt of $0). The comparison tables above allow you to evaluate Zynerba Pharmaceuticals relative to 5 sector peers and leading companies across all cannabis sub-sectors, helping you identify which stocks offer better value, stronger growth, or more favorable risk profiles.

Frequently Asked Questions

How does ZYNE compare to other Biotech stocks?+

Zynerba Pharmaceuticals has a market cap of $33.8M, placing it among 6 companies in the Biotech sector. Its price-to-sales ratio is N/A and its gross margin is 0.0%. Use the table above to compare these metrics against every Biotech peer.

What is ZYNE's biggest competitor?+

By market capitalization, the closest comparable company is C21 Investments (CXXIF) with a market cap of $33.5M. Click the compare link to view a full head-to-head analysis.

Is ZYNE overvalued compared to its peers?+

Zynerba Pharmaceuticals trades at a P/S ratio of N/A. Compare this to sector peers in the table above to determine relative valuation. A lower P/S may indicate relative value, while a higher P/S may reflect growth expectations.

Which cannabis stock has better margins than ZYNE?+

Zynerba Pharmaceuticals has a gross margin of 0.0%. Among its Biotech peers, 1 companies report higher gross margins. See the Sector Peers table for a full ranking.

Can I compare ZYNE to stocks in other cannabis sectors?+

Yes. The Cross-Sector Comparisons section above features top companies from sectors outside Biotech. You can click any company to see a full side-by-side comparison with ZYNE covering price, valuation, financials, and growth metrics.

ZYNE Stock Overview ZYNE Financials ZYNE News ZYNE Investment Analysis Biotech Sector Stocks All Cannabis Stocks

Disclaimer: The comparison data on this page is for informational purposes only and does not constitute financial advice, investment recommendations, or an endorsement of any security. Cannabis stocks are highly volatile and subject to unique regulatory risks. Always conduct your own research and consult a licensed financial advisor before making investment decisions.Cannabismarketcap does not guarantee the accuracy or completeness of any data presented.

Compare Zynerba Pharmaceuticals (ZYNE) With Other Cannabis Stocks

Biotech Sector Peers

Top Matchups by Market Cap

Cross-Sector Comparisons

Comparing ZYNE in the Cannabis Market

Frequently Asked Questions

Related Pages